1. Scrip

From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo

 
• By Lisa Takagi

When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company? 

Communication was always the key for Daiichi Sankyo's transformation under Nakayama's leadership.
Communication was always the key for Daiichi Sankyo's transformation under Nakayama's leadership. • Source: Shutterstock

It was just several years ago when Daiichi Sankyo Co., Ltd.’s first antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) was launched in the US, helped by the Japanese company’s largest collaborative deal ever at the time, with AstraZeneca PLC.

The ADC has been the firm’s mainstay since then, becoming a blockbuster on the back of its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.